BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18327815)

  • 1. Editorial. Endometrioid epithelial ovarian cancer.
    Cibull ML; Karabakhtsian RG
    Cancer; 2008 May; 112(10):2108-11. PubMed ID: 18327815
    [No Abstract]   [Full Text] [Related]  

  • 2. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
    Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
    Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer.
    Jager W; Sauerbrei W; Beck E; Maassen V; Stumpfe M; Meier W; Kuhn W; Janicke F
    Anticancer Res; 1995; 15(6B):2639-42. PubMed ID: 8669839
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
    Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
    Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
    Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
    Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
    Yuan SF; Zhang LP; Zhu LJ; Chen WJ; Zheng WE; Xiong JP
    Asian Pac J Cancer Prev; 2013; 14(6):3949-53. PubMed ID: 23886213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of race on survival in uterine serous carcinoma: a hospital-based study.
    Al-Wahab Z; Ali-Fehmi R; Cote ML; Elshaikh MA; Ibrahim DR; Semaan A; Schultz D; Morris RT; Munkarah AR
    Gynecol Oncol; 2011 Jun; 121(3):577-80. PubMed ID: 21377196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis.
    Heatley MK
    Histopathology; 2005 Apr; 46(4):468. PubMed ID: 15810962
    [No Abstract]   [Full Text] [Related]  

  • 10. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
    Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous endometrial malignant mixed mesodermal tumor and ovarian serous adenocarcinoma.
    Krigman HR; Coogan AC; Marks JR
    Arch Pathol Lab Med; 1995 Jan; 119(1):99-103. PubMed ID: 7802567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
    Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
    J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.
    Tripodi E; Cormio G; De Giorgi U; Valabrega G; Rubino D; Lepori S; Maltese G; Sabatucci I; Lorusso D
    Int J Gynecol Cancer; 2019 Jan; 29(1):153-157. PubMed ID: 30640698
    [No Abstract]   [Full Text] [Related]  

  • 15. [Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer].
    Ivanov S; Batashki I
    Akush Ginekol (Sofiia); 2008; 47(5):9-11. PubMed ID: 19227770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of low-grade serous ovarian cancer.
    Plaxe SC
    Am J Obstet Gynecol; 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. PubMed ID: 18395040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Uterine papillary serous carcinoma--a different kind of tumor].
    Steinman N; Avni A
    Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.